Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the progression free survival of capecitabine
(Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic
esophagogastric adenocarcinomas.